Nura Bio
PrivateLast Round
Series B
Jun 22, 2026
Total Funding Raised
$214.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nura Bio is a biotechnology company that develops neuroprotective therapies aimed at preventing neuronal loss and enhancing immune function in the nervous system following neurological injuries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nura Bio Comparables
Compare Nura Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tenvie Therapeutics | 89% | |
| Sironax | 87% | |
| QurAlis | 83% |
Nura Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 22, 2026 | ||||
| Series A Extension | Sep 17, 2024 | ||||
| Series A | Jul 29, 2020 |
Key People
Founding team and executive leadership
Nura Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A, Series B, Series A Extension |
| The Chernin Group | Series A, Series A Extension |
| Sanofi Ventures | Series B, Series A Extension |
| Samsara BioCapital | Series A, Series B, Series A Extension |
| Euclidean Capital | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 56% MoM.
- Jun 22, 2026
$74M round led by The Column Group.
Recent news
Latest coverage and updates
- is_developingJul 30, 2026
Nura Bio, Inc. is developing neuroprotective small molecule therapies for the treatment of neurological diseases, including ALS.
- receives_financingJun 22, 2026
Nura Bio, Inc. received financing of $73.8M in Series B on Jun 22nd '26.
Nura Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nura Bio's valuation, stock price, and market status.
Is Nura Bio a public or private company?
Nura Bio is a private company.
What is the current stock price of Nura Bio?
Nura Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Nura Bio worth (valuation)?
Valuation information for Nura Bio is not publicly available.
Can I buy Nura Bio stock?
Nura Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nura Bio's last funding round?
Nura Bio's most recent funding round was Series B on June 22, 2026.
Who are the main investors in Nura Bio?
Key investors in Nura Bio include The Column Group, The Chernin Group.
Will Nura Bio IPO soon?
No public IPO plans have been announced for Nura Bio.
How can I track Nura Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nura Bio's secondary market activity and sign up for updates.